New combo therapy aims to boost immune attack on stomach cancer
NCT ID NCT07277439
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding an immune-boosting drug (thymosin alpha 1) to standard chemo-immunotherapy can improve outcomes for people with stage III gastroesophageal junction cancer. About 48 participants will receive either the standard treatment or the standard plus thymosin before surgery. The goal is to see if the combination leads to more complete tumor disappearance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
First Affiliated Hospital of Nanjing Medical Unviersity
RECRUITINGNanjing, Jiangsu, 210000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can surgery for stomach or esophageal cancer cloud the mind?